OnabotulinumtoxinA in Migraine: A Review of the Literature and Factors Associated with Efficacy

The efficacy of onabotulinumtoxinA (OnaB-A) as a preventative treatment for chronic migraine, emerging fortuitously from clinical observation is now supported by class one evidence and over two decades of real-world clinical data. There is still limited ability to predict a clinically meaningful res...

Descripción completa

Detalles Bibliográficos
Autores principales: Ray, Jason C., Hutton, Elspeth J., Matharu, Manjit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8269087/
https://www.ncbi.nlm.nih.gov/pubmed/34209849
http://dx.doi.org/10.3390/jcm10132898
_version_ 1783720497703288832
author Ray, Jason C.
Hutton, Elspeth J.
Matharu, Manjit
author_facet Ray, Jason C.
Hutton, Elspeth J.
Matharu, Manjit
author_sort Ray, Jason C.
collection PubMed
description The efficacy of onabotulinumtoxinA (OnaB-A) as a preventative treatment for chronic migraine, emerging fortuitously from clinical observation is now supported by class one evidence and over two decades of real-world clinical data. There is still limited ability to predict a clinically meaningful response to OnaB-A for individual patients, however. This review summarises briefly the proposed mechanism of OnaB-A in chronic migraine, the literature of predictors of clinical response, and recent developments in the field.
format Online
Article
Text
id pubmed-8269087
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82690872021-07-10 OnabotulinumtoxinA in Migraine: A Review of the Literature and Factors Associated with Efficacy Ray, Jason C. Hutton, Elspeth J. Matharu, Manjit J Clin Med Review The efficacy of onabotulinumtoxinA (OnaB-A) as a preventative treatment for chronic migraine, emerging fortuitously from clinical observation is now supported by class one evidence and over two decades of real-world clinical data. There is still limited ability to predict a clinically meaningful response to OnaB-A for individual patients, however. This review summarises briefly the proposed mechanism of OnaB-A in chronic migraine, the literature of predictors of clinical response, and recent developments in the field. MDPI 2021-06-29 /pmc/articles/PMC8269087/ /pubmed/34209849 http://dx.doi.org/10.3390/jcm10132898 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Ray, Jason C.
Hutton, Elspeth J.
Matharu, Manjit
OnabotulinumtoxinA in Migraine: A Review of the Literature and Factors Associated with Efficacy
title OnabotulinumtoxinA in Migraine: A Review of the Literature and Factors Associated with Efficacy
title_full OnabotulinumtoxinA in Migraine: A Review of the Literature and Factors Associated with Efficacy
title_fullStr OnabotulinumtoxinA in Migraine: A Review of the Literature and Factors Associated with Efficacy
title_full_unstemmed OnabotulinumtoxinA in Migraine: A Review of the Literature and Factors Associated with Efficacy
title_short OnabotulinumtoxinA in Migraine: A Review of the Literature and Factors Associated with Efficacy
title_sort onabotulinumtoxina in migraine: a review of the literature and factors associated with efficacy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8269087/
https://www.ncbi.nlm.nih.gov/pubmed/34209849
http://dx.doi.org/10.3390/jcm10132898
work_keys_str_mv AT rayjasonc onabotulinumtoxinainmigraineareviewoftheliteratureandfactorsassociatedwithefficacy
AT huttonelspethj onabotulinumtoxinainmigraineareviewoftheliteratureandfactorsassociatedwithefficacy
AT matharumanjit onabotulinumtoxinainmigraineareviewoftheliteratureandfactorsassociatedwithefficacy

Ejemplares similares